Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy.
OBJECTIVE
To report the short term anatomical and visual acuity response after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.


METHODS
Ten eyes having proliferative diabetic retinopathy were treated with at least one intravitreal injection of bevacizumab, 1.25 mg in 0.05 mL. Patients underwent complete ophthalmologic evaluation at baseline and follow up visits including Snellen's best corrected visual acuity (BCVA), fundus biomicroscopy and fluorescein angiography. Vitreous hemorrhage precluding laser treatment was present in 6 eyes.


RESULTS
Follow up ranged between 3 and 6 months (mean 4.2 +/- 1.23 months). Improvement of vision was observed after one week with BCVA improved to 0.47 +/- 0.26 compared with baseline BCVA of 0.365 +/- 0.26 (P < 0.05). At last follow up, BCVA was 0.65 +/- 0.33. Seven eyes had better visual acuity. Vitreous hemorrhage cleared completely in 4 eyes while 2 eyes had residual vitreous hemorrhage. Regression of retinal neovascularization was complete in 7 eyes, incomplete in 3 eyes. Regression was observed as early as 2 weeks after first injection. Reperfusion after regression was observed in 2 eyes. Patients received a mean of 1.7 +/- 0.67 injections per eye. No complications were noted in all eyes. Pancryopexy was done in 1 eye and additional laser was done in 2 eyes.


CONCLUSIONS
Intravitreal bevacizumab was safe and effective in treatment of proliferative diabetic retinopathy. It can induce effective regression of retinal neovascularization and rapid clearance of vitreous hemorrhage. It can be used as an adjunctive therapy with laser photocoagulation and to enhance absorption of vitreous hemorrhage with subsequent deferral from vitrectomy.


CONCLUSIONS
Ten eyes having proliferative diabetic retinopathy were treated with intravitreal bevacizumab. Following injection, evident regression of retinal neovascularization and rapid clearance of vitreous hemorrhage as well as vision improvement was observed.
El-Batarny
Ashraf M
AM
Tanta University, Tanta, Egypt; Magrabi Eye and Ear Hospital, PO Box 513, P C 112, Muscat, Sultanate of Oman. elbatarny@hotmail.com